In ongoing studies, Adagrasib (an inhibitor of the RAS GTPase family) demonstrated anti-tumour activity (CRC and NSCLC) in the KRYSTAL-1 phase I/II study conducted among heavily pretreated patients with KRAS G12 C mutations.49,50. This evidence concerns the gene KRAS and non-small cell lung carcinoma.